Status: Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.
Participants needed: 132
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: MOMA TherapeuticsUpdated: Apr 15, 2026Locations: 14
Eligibility criteria
Age ≥ 18 years [+7]
Known Werner Syndrome [+12]